desflurane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
halogenated compounds used as general inhalation anaesthetics 811 57041-67-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • desflurane
A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.
  • Molecular weight: 168.04
  • Formula: C3H2F6O
  • CLOGP: 1.51
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 9.23
  • ALOGS: -1.68
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 18, 1992 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serotonin syndrome 83.38 40.14 29 1244 24684 50579167
Procedural hypotension 79.52 40.14 15 1258 1087 50602764
Neuromuscular block prolonged 77.03 40.14 13 1260 498 50603353
Bradycardia 68.46 40.14 33 1240 64393 50539458
Cardiac arrest 65.93 40.14 35 1238 83616 50520235
Hyperthermia malignant 65.72 40.14 12 1261 727 50603124
Anaphylactic shock 61.64 40.14 22 1251 20133 50583718
Anaphylactic reaction 58.34 40.14 28 1245 54027 50549824
Delayed recovery from anaesthesia 46.57 40.14 9 1264 740 50603111
Vitamin K deficiency 45.02 40.14 8 1265 415 50603436
Bronchospasm 44.58 40.14 16 1257 14838 50589013
Unwanted awareness during anaesthesia 41.21 40.14 7 1266 278 50603573

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 168.92 44.05 32 981 1752 29571762
Anaphylactic shock 104.93 44.05 32 981 13304 29560210
Seizure like phenomena 89.99 44.05 16 997 610 29572904
Serotonin syndrome 72.92 44.05 26 987 17486 29556028
Bronchospasm 58.56 44.05 19 994 9590 29563924
Neuromuscular block prolonged 48.13 44.05 9 1004 454 29573060
Anticholinergic syndrome 47.97 44.05 10 1003 884 29572630

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 215.10 34.96 42 2403 2417 64493870
Serotonin syndrome 145.58 34.96 55 2390 39227 64457060
Anaphylactic shock 144.07 34.96 51 2394 30277 64466010
Neuromuscular block prolonged 118.65 34.96 22 2423 955 64495332
Bronchospasm 97.36 34.96 35 2410 21647 64474640
Post procedural complication 90.38 34.96 33 2412 21320 64474967
Cardiac arrest 79.24 34.96 57 2388 154007 64342280
Bradycardia 77.95 34.96 51 2394 118168 64378119
Anaphylactic reaction 74.94 34.96 41 2404 68623 64427664
Delayed recovery from anaesthesia 74.05 34.96 16 2429 1512 64494775
Seizure like phenomena 72.81 34.96 16 2429 1636 64494651
Procedural hypotension 70.70 34.96 16 2429 1870 64494417
Anticholinergic syndrome 60.13 34.96 15 2430 2654 64493633
Trigemino-cardiac reflex 52.95 34.96 9 2436 235 64496052
Drug interaction 51.94 34.96 66 2379 362017 64134270
Circulatory collapse 47.76 34.96 24 2421 33708 64462579
Hypotension 47.75 34.96 65 2380 380909 64115378
Recurrence of neuromuscular blockade 47.55 34.96 8 2437 196 64496091
Laryngospasm 46.97 34.96 13 2432 3432 64492855
End-tidal CO2 increased 38.50 34.96 5 2440 17 64496270
Unwanted awareness during anaesthesia 38.34 34.96 7 2438 278 64496009
Procedural vomiting 38.01 34.96 8 2437 666 64495621
Vitamin K deficiency 37.95 34.96 8 2437 671 64495616
Procedural nausea 37.78 34.96 8 2437 686 64495601
Subcutaneous emphysema 36.03 34.96 9 2436 1600 64494687

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AB07 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Halogenated hydrocarbons
CHEBI has role CHEBI:38870 inhalation anesthetics
MeSH PA D000777 Anesthetics
MeSH PA D018685 Anesthetics, Inhalation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
FDA EPC N0000175681 General Anesthetic
FDA PE N0000175975 General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Hyperkalemia contraindication 14140009
Cirrhosis of liver contraindication 19943007 DOID:5082
Viral hepatitis C contraindication 50711007 DOID:1883
Viral hepatitis type B contraindication 66071002 DOID:2043
Benign intracranial hypertension contraindication 68267002 DOID:11459
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Myasthenia gravis contraindication 91637004 DOID:437
Disease of liver contraindication 235856003 DOID:409
Neuromyopathy contraindication 255522009 DOID:440
Familial periodic paralysis contraindication 267607008 DOID:1029
Lesion of brain contraindication 301766008
Malignant hyperthermia contraindication 405501007
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium channel subfamily K member 2 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 3 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 9 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 10 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 18 Ion channel OPENER CHEMBL CHEMBL
Glycine receptor (alpha-1/beta) Ion channel POSITIVE MODULATOR CHEMBL CHEMBL
GABA-A receptor; anion channel Ion channel POSITIVE ALLOSTERIC MODULATOR CHEMBL CHEMBL

External reference:

IDSource
4020649 VUID
N0000148295 NUI
D00546 KEGG_DRUG
27340 RXNORM
4020649 VANDF
C0063252 UMLSCUI
CHEBI:4445 CHEBI
DSF PDB_CHEM_ID
CHEMBL1200733 ChEMBL_ID
DB01189 DRUGBANK_ID
D000077335 MESH_DESCRIPTOR_UI
42113 PUBCHEM_CID
6505 INN_ID
7156 IUPHAR_LIGAND_ID
CRS35BZ94Q UNII
247482 MMSL
4545 MMSL
d02374 MMSL
004114 NDDF
108393001 SNOMEDCT_US
386841003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Suprane HUMAN PRESCRIPTION DRUG LABEL 1 0404-9961 LIQUID 240 mL RESPIRATORY (INHALATION) NDA 23 sections
Desflurane HUMAN PRESCRIPTION DRUG LABEL 1 0781-6172 LIQUID 240 mL RESPIRATORY (INHALATION) ANDA 27 sections
SUPRANE HUMAN PRESCRIPTION DRUG LABEL 1 10019-641 LIQUID 240 mL RESPIRATORY (INHALATION) NDA 26 sections
Suprane HUMAN PRESCRIPTION DRUG LABEL 1 10019-644 LIQUID 240 mL RESPIRATORY (INHALATION) NDA 27 sections
SUPRANE HUMAN PRESCRIPTION DRUG LABEL 1 10019-646 LIQUID 240 mL RESPIRATORY (INHALATION) NDA 26 sections
Suprane HUMAN PRESCRIPTION DRUG LABEL 1 52584-641 LIQUID 240 mL RESPIRATORY (INHALATION) NDA 23 sections